ALZpath

Executive Summary

ALZpath is a San Diego-based private diagnostics company founded in 2022, specializing in early detection and monitoring of Alzheimer's disease and other neurodegenerative conditions through novel biomarkers. The company aims to address the critical need for accessible, accurate diagnostic tools that can enable earlier intervention and improve patient outcomes. Leveraging proprietary biomarker platforms, ALZpath is developing blood-based tests that could offer a less invasive and more scalable alternative to current imaging and cerebrospinal fluid-based methods. Although still in early development stages, the company's focus on a high-need area with growing global prevalence positions it well within the neuroscience diagnostics landscape. Success will depend on clinical validation, regulatory clearance, and strategic partnerships to compete with established players.

Upcoming Catalysts (preview)

• Q2 2027Initial Clinical Validation Data60% success
• Q4 2026FDA Breakthrough Device Designation40% success
• Q3 2027Strategic Partnership or Licensing Deal35% success